ACHIEVEMENT OF LDL-C GOALS IN PATIENTS AT MODERATE TO VERY HIGH CARDIOVASCULAR RISK ON LIPID-LOWERING DRUG THERAPY (CEPHEUS II)

被引：1
|
作者：
Logunova, Natalia [1 ]
Gurina, Natalia [1 ]
Boytsov, Sergey [2 ]
机构：
[1] AstraZeneca, Dept Med, Moscow, Russia
[2] Minist Hlth, State Res Ctr Prevent Med, Moscow, Russia
来源：
ATHEROSCLEROSIS | 2017年 / 263卷
关键词：
D O I：
10.1016/j.atherosclerosis.2017.06.770
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO417
引用
收藏
页码：E236 / E237
页数：2
相关论文
共 50 条
  • [31] STATIN TREATED PATIENTS AT VERY HIGH CARDIOVASCULAR RISK IN EUROPE: ARE THE MAJORITY CLOSE TO LDL-C
    Lautsch, D.
    Gitt, A. K.
    Brudi, P.
    Vanneste, B.
    Ambegaonkar, B.
    ATHEROSCLEROSIS, 2014, 235 (02) : E35 - E35
  • [32] COST-EFFECTIVENESS OF LDL-C LOWERING WITH EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN THE UNITED STATES
    Gandra, S. R.
    Villa, G.
    Fonarow, G.
    Lothgren, M.
    Lindgren, P.
    Somaratne, R.
    van Hout, B.
    VALUE IN HEALTH, 2016, 19 (03) : A3 - A3
  • [33] Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
    Gandra, Shravanthi R.
    Villa, Guillermo
    Fonarow, Gregg C.
    Lothgren, Mickael
    Lindgren, Peter
    Somaratne, Ransi
    van Hout, Ben
    CLINICAL CARDIOLOGY, 2016, 39 (06) : 313 - 320
  • [34] Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk
    Mostaza, Jose Maria
    Escobar, Carlos
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (07)
  • [35] Early combination lipid-lowering therapy is associated with greater achievement of goal LDL-C: Insights from the OPTIMIZE PAD-1 trial
    Hess, Connie N.
    Daffron, Ashley
    Nehler, Mark R.
    Szarek, Michael
    Cannon, Christopher P.
    Hsia, Judith
    Saseen, Joseph J.
    Bonaca, Marc P.
    VASCULAR MEDICINE, 2025,
  • [36] Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C
    Katzmann, Julius L.
    Sorio-Vilela, Francesc
    Dornstauder, Eugen
    Fraas, Uwe
    Smieszek, Timo
    Zappacosta, Sofia
    Laufs, Ulrich
    CLINICAL RESEARCH IN CARDIOLOGY, 2022, 111 (03) : 243 - 252
  • [37] Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C
    Julius L. Katzmann
    Francesc Sorio-Vilela
    Eugen Dornstauder
    Uwe Fraas
    Timo Smieszek
    Sofia Zappacosta
    Ulrich Laufs
    Clinical Research in Cardiology, 2022, 111 : 243 - 252
  • [38] Extremely high-risk patients with acute coronary syndrome: How "extreme" should lipid-lowering therapy be if the LDL-C target <40 mg/dl is considered?
    Rallidis, Loukianos S.
    Tsamoulis, Donatos
    Leventis, Ioannis
    Kalogeras, Petros
    Delakis, Iosif
    Samiotis, Elefterios
    Kalantzis, Charalampos
    Malkots, Belkis
    Tasoulas, Dimitrios
    Bouratzis, Vasileios
    Eleutheriou, Dimitris
    Dalos, Styliano
    Potoupni, Victoria
    Zervakis, Stelio
    Xygka, Georgia
    Miliotou, Argyro
    Papathanasiou, Konstantinos A.
    Vlachopoulos, Charalambos
    KARDIOLOGIA POLSKA, 2023, 81 (10) : 1012 - 1014
  • [39] Evinacumab Lowers LDL-C in Patients With Homozygous Familial Hypercholesterolemia Irrespective of Background Lipid-lowering Medication
    Raal, Frederick J.
    Rosenson, Robert S.
    Reeskamp, Laurens F.
    Hovingh, G. Kees
    Kastelein, John J.
    Rubba, Paolo
    Ali, Shazia
    Banerjee, Poulabi
    Chan, Kuo-Chen
    Khilla, Nagwa
    McGinniss, Jennifer
    Pordy, Robert
    Zhang, Yi
    Gaudet, Daniel
    CIRCULATION, 2020, 142
  • [40] Reaching LDL-C Targets in Patients with Moderate, High, and Very High Risk for Cardiovascular Disease After Bariatric Surgery According to Different Guidelines
    Ponce de Leon-Ballesteros, Guillermo
    Sanchez-Aguilar, Hugo A.
    Aguilar-Salinas, Carlos A.
    Herrera, Miguel F.
    OBESITY SURGERY, 2021, 31 (05) : 2087 - 2096
12345